TAMPA, June 7, 2016 /PRNewswire/ -- People who suffer from moderate to severe psoriatic arthritis have a potential opportunity
Psoriatic arthritis is a chronic disease that causes inflammation of the skin and joints. The condition affects 30 percent of men and women and usually begins as psoriasis of the skin, and then in 15-to-25-percent of cases, it progresses to psoriatic arthritis, which affects the joints. "We're enrolling people in the trial whose daily lives are affected by the disease," said Seth Forman, M.D., principal investigator of Forward Clinical Trials who is leading the study. Psoriatic arthritis usually appears between the ages of 30 and 55, but can be diagnosed during childhood. The inflammation it causes can affect the entire body and lead to permanent joint and tissue damage if not treated immediately.
Secukinumab is an FDA-approved drug used to ease the symptoms of moderate to severe psoriasis. It is predominately prescribed to adults who do not respond to other medications. Based on recent case studies, Secukinumab is known to significantly improve overall symptoms of psoriatic arthritis and provides patients with clear skin or almost clear skin during their first 12 weeks of treatment. "We've had trial patients tell us they are free from pain for the first time in years and they finally have their lives back, including some who no longer have to wear head-to-toe clothing to hide their condition," added Forman.
Forman is currently conducting trials for eczema, psoriasis, and psoriatic arthritis and plans to begin another eczema trial just for pediatric patients in September. Patients or parents of patients interested in the trial can learn more by watching this video, and apply by visiting http://www.forwardclinicaltrials.com/ or calling (813) 264-2155.
About Forward Clinical Trials:Forward Clinical Trials (FCT) is a multi-specialty clinical trials practice that provides new, innovative medicines of the future. FCT is located in Tampa, Fla. It is led by Seth B. Forman, M.D., a board-certified dermatologist and founder of Forman Dermatology & Skin Cancer Institute. Founded in 2012, FCT is a multispecialty research site conducting Phase II IV studies. FCT participates in trials involving investigational and FDA-approved drugs. For more information, visit us at www.formanderm.com or on Facebook.
Media Contacts:Molly CollinsEmail(850) 559-7107
Jeannie SalamehEmail(727) 644-5010
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tampa-dermatologist-launches-clinical-trial-for-psoriatic-arthritis-patients-300280701.html
SOURCE Forward Clinical Trials
Subscribe to our Free Newsletters!
Hand hygiene is a simple and affordable technique to prevent infections.
Erythropoietin is a hormone secreted by kidneys in response to low oxygen levels in tissues ...
Local anesthesia is a type of anesthesia generally used to block pain sensation only in a specific ...View All